

RESEARCH ARTICLE

Analysis on Clinical Characteristics and Influencing Factors of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma

Wei Zheng^{1&}, Yuan-Ji Xu^{2&}, Su-Fang Qiu¹, Jing-Feng Zong¹, Ling-Ling Huang², Chao-Bin Huang¹, Shao-Jun Lin¹, Jian-Ji Pan^{1,2*}

Abstract

Background: To explore the independent prognostic factors for the recurrence/metastasis of patients with locoregionally advanced nasopharyngeal carcinoma (LANPC). **Materials and Methods:** A total of 604 patients initially diagnosed as LANPC by pathohistology in Fujian Provincial Cancer Hospital were selected to analyze the relationship between the clinical pathological patterns, therapeutic protocols and clinical stages with the recurrence/metastasis of LANPC. **Results:** The 1-, 3- and 5-year locoregionally recurrent rates of LANPC patients were 2.0%, 9.5% and 12.9% respectively, with average recurrent period being 78 months. Univariate analysis results indicated that clinical stages had certain influence on the recurrent period of LANPC patients. However, COX regression models showed that ages, genders and clinical stages were not the independent prognostic factors influencing the recurrence. The 1-, 3- and 5-year metastatic rates of LANPC patients were 6.6%, 17.5% and 18.8% respectively, with average metastatic period of 73 months. Univariate analysis results demonstrated that ages, N stages, clinical stages, locations of lymph node, retropharyngeal lymph node and extracapsular invasion of lymph node had certain influence on the metastatic period of LANPC patients. Additionally, further COX regression analysis results suggested that T stages, reduction protocols and extracapsular invasion of lymph node were the independent prognostic factors influencing the metastasis of patients with LANPC, in which T stages and extracapsular invasion of lymph node were the pestilent factors while reduction protocols the protective factor. **Conclusions:** Induction chemotherapy is beneficial to LANPC patients with initial treatment, and the metastatic rate decreases greatly after the application of reduction chemotherapy.

Keywords: Locoregionally advanced nasopharyngeal carcinoma - induction chemotherapy - radiotherapy - recurrence

Asian Pac J Cancer Prev, 16 (10), 4393-4399

Introduction

Nasopharyngeal carcinoma (NPC) is one of the most common head-neck malignant tumors in China, with especially high morbidity in the south region. The morbidity of NPC in Guangdong Province ranks the third in all malignant tumors and the first in head-neck tumors (Hu et al., 2014; Li et al., 2014), and with significant racial, regional and family aggregation phenomenon (Qu et al., 2015). Radiotherapy is the primary therapeutic method for locoregional advanced NPC (LANPC) because LANPC is sensitive to radiotherapy. In recent years, with the wide application of intensity modified radiation therapy (IMRT) and comprehensive therapies, the therapeutic efficacy for NPC patients has been further improved and the 5-year local recurrence free survival rate is up to 78.4%~80% (Lin et al., 2014; Lee et al., 2014; Wu et al., 2014). However, the therapeutic efficacy for LANPC patients is still unsatisfactory and the 5-year survival rate

is only 70% (Wu et al., 2014). Recurrence and metastasis are commonly seen after the initial treatment of LANPC, which can lead to the failure rate of first-cycle radiotherapy up to 25%. Moreover, distant metastasis is the primary failure model, accounting for 53.6%~63.1% of the whole recurrence, followed by the locoregional recurrence and regional lymph node metastasis (Chen et al., 2013; Zeng et al., 2014). At present, radiochemotherapy is still the major protocol for the treatment of LANPC patients, and in order to further improve its therapeutic efficacy, the independent prognostic factors influencing the therapeutic failure models should be firstly explored. Therefore, this study analyzed the clinical data of 604 LANPC patients and explored the relationship between clinical pathological characteristics and therapeutic protocols with the LANPC recurrence/metastasis, aiming to search the independent risk factors for LANPC patients with recurrence/metastasis and predicate the clinical efficacy of secondary-cycle treatment after recurrence, so as to

¹Department of Radiation Oncology, Fujian Provincial Cancer Hospital, ²The Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China [&]Equal contributors *For correspondence: panjianji@aliyun.com

provide theoretical basis for the establishment of standard therapeutic protocols for patients with LANPC.

Materials and Methods

General data

This study was approved by the Ethics Committee of Fujian Provincial Cancer Hospital and all informed consent forms were signed by the patients and (or) their families. Totally 604 patients initially diagnosed as LANPC without metastasis who were admitted in Fujian Provincial Cancer Hospital from June, 2005 to October, 2007 were selected. All patients were confirmed by pathology and classified into stage III and IV according to the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) criteria for NPC (the 7th version). There were 466 males and 138 females, in which 395 were ≤ 50 years and 209 > 50 years; 575 were with squamous carcinoma and 29 with non-squamous carcinoma; T stages: 48 in stage T1, 61 in T2, 342 in T3 and 153 in T4; N stages: 49 in stage N0, 248 in N1, 247 in N2 and 60 in N3; clinical stages: 401 in stage III, and 203 in stage IV; locations of lymphadenovary: 165 patients without lymphadenovary, 347 on upper neck, 67 on lower neck and 25 on clavicle; 476 were with retropharyngeal lymph node; and 370 were with extracapsular invasion of lymph node.

Methods

Evaluation before treatment: Evaluation before treatment included record analysis and physical examination, the latter of which was consisted of blood routine, nasopharyngoscope, magnetic resonance image (MRI) on nasopharynx and neck, chest X ray or CR scan, abdominal color ultrasound or MRI, electrocardiogram and emission CT (ECT) bone image. Partial patients also needed examination with positron emission computed tomography (ECT), which was decided by the doctor-in-charge according to the patients' practical conditions.

Initial therapeutic outcome: Radical radiotherapy was given to all patients, in which 399 with routine radiotherapy and 205 with IMRT; the total radiotherapeutic dosage on nasopharynx was 66.00~85.60 Gy with average one of (70.87 ± 3.10) Gy, and radiotherapeutic times were 30~40 times with average ones being (34.01 ± 2.38) times; the maximum radiotherapeutic dosage for lymph node was 50.00~79.00 Gy with average one of (65.44 ± 5.19) Gy, and the radiotherapeutic times for neck were 25~39 times with average ones being (32.00 ± 2.46) times. The detailed techniques referred to the previously reported research by Cancer Hospital of Fujian Medical University (Lin et al., 2009; Xu et al., 2010). Additionally, emergency treatments, including surgery, dimensional conformal radiation therapy (3D-CRT), chemotherapy, intracavitary brachytherapy and intensity modulated radiation therapy (IMRT) were given to patients who had persistent or relapse diseases.

Of all patients, 549 received chemotherapy, in which 153 were treated with recurrent chemotherapy, 104 with 1-cycle chemotherapy and 49 with > 2 -cycle chemotherapy. The administrative protocols included:

i) cisplatin, 80~100 mg/m², d1~d3, 21 d as a cycle; *ii*) paclitaxel, 135 mg/m², d1 and cisplatin, 80~100 mg/m², d1~d3, 21 d as a cycle; *iii*) gemcitabine, 1000 mg/m², d1 and d8 and cisplatin, 80~100 mg/m², d1~d3, 21 d as a cycle; *iv*) fluorouracil, 800 mg/m², d1~d5 and cisplatin, 80~100 mg/m², d1~d3, 21 d as a cycle. The detailed chemotherapeutic cycles and administrative protocols were determined by the doctor-in-charge according to the practical conditions of patients. A total of 520 patients received induction chemotherapy, in which 36 received 1-cycle and 484 > 2 -cycle chemotherapy. The intervals of induction chemotherapy were 2 weeks, and radiotherapy was conducted within 1 week after the second-cycle induction chemotherapy. Induction protocols: 444 patients were treated with paclitaxel plus platinum, 13 with gemcitabine plus platinum and 63 with fluorouracil plus platinum, whose administrative dosage and times were the same with those of concurrent chemotherapy. Moreover, 98 patients were treated with adjuvant cisplatin-based chemotherapy accepting the advices of the attending radiation oncologists.

Follow up: The median follow-up period was 65 months (3~86 months) in this study. The primary endpoint of the follow up was overall survival (OS) and second endpoints were progression-free survival (PFS), locoregional free survival (LRFS) and distant metastasis-free survival (DMFS). During the treatment, all patients were evaluated 1 time/week. After treatment, they were followed up 1 time/3 months within the first 2 years, and 1 time/6 months in the next 3 years and then 1 time/year every year.

Observational indexes

The recurrence and metastasis were observed to analyze the relevance between recurrence/metastasis with clinical pathological characteristics and therapeutic protocols. The periods of recurrence and metastasis were recorded to analyze the influence of each factor on recurrence/metastasis of LANPC patients.

Statistical data analysis

Double input of data obtained after follow up was performed with EpiData 3.0. SPSS 17.0 and SAS 9.3 software were applied for all data analysis. As to categorical variables, the frequency and percentage of each variable were calculated and detected by χ^2 test or continuous correction χ^2 test whereas rank categorical variables were detected with χ^2 trend test. Life table was applied to calculate the 1-, 3- and 5-year DMFS and LRFS and Log-Rank test was adopted to compare the differences among groups. COX stepwise regression analysis was used to determine the relevant factors influencing the recurrence and metastasis of LANPC. $P < 0.05$ was considered to be statistically significant.

Results

Analysis on relevance between recurrence and each factor

The recurrent rate was evidently lower in patients in clinical stage III than those in IV ($P < 0.05$) and was apparently lower in survival patients than those died

($P<0.01$); the different T stages were in close association with recurrence ($P<0.05$); but there was no significant difference between the rest factors and recurrence ($P>0.05$) (Table 1).

Influence of each factor on recurrent time

The life table method was applied to analyze the follow-up data of all patients, and the results indicated that the 1-, 3- and 5-year recurrent rates of LANPC patients were 2.0%, 9.5% and 12.9% respectively, with average recurrent period being 78 months (95% confidence intervals: 76.43~79.86 months).

In order to observe the influence of each factor on recurrent period, log-rank test was adopted, in which ages, pathological patterns, T stages, N stages, concurrent chemotherapy, locations of lymphadenovarix, retropharyngeal lymph node, chemotherapeutic cycles, induction chemotherapy and the induction protocols were excluded from the test due to their values, while the rest

factor results were shown in Table 2. It was suggested in the table that clinical patterns and death had certain influence on the recurrent period of LANPC patients whereas the rest factors had no impact.

On this basis, genders, ages, pathological patterns, T stags, N stags, radiotherapeutic techniques, concurrent chemotherapy, locations of lymphadenovarix, induction chemotherapeutic protocols, retropharyngeal lymph node, chemotherapeutic cycles, extracapsular invasion of lymph node and metastasis were set as the variates to conduct the multivariate analysis with COX risk ratio regression models (clinical stages were excluded from the analysis due to the high association with TNM stages). It was believed that the above factors were not the independent prognostic factors influencing the recurrence of LANPC because there was no significant difference according to the terminal COX regression equation ($\chi^2=23.758$, $P=0.126$).

Table 1. Analysis on Relevance between Recurrence and Each Factor

Influencing factors		Without recurrence (n)	With recurrence (n)	N	χ^2 value	P value
Gender	Male	408	58	466	0.249	0.618
	Female	123	15	138		
Ages (years)	≤ 50	348	47	395	0.038	0.846
	> 50	183	26	209		
Pathological patterns	Squamous carcinoma	507	68	575	0.338	0.561
	Non-squamous carcinoma	24	5	29		
T stages	1	43	5	48	9.035	0.029
	2	52	9	61		
	3	311	31	342		
	4	125	28	153		
N stages	0	47	2	49	3.591	0.309
	1	216	32	248		
	2	217	30	247		
Clinical stages	III	362	39	401	6.256	0.012
	IV	169	34	203		
Radiotherapeutic techniques	Routine radiotherapy	346	53	399	1.586	0.208
	IMRT	185	20	205		
Concurrent chemotherapy	No	399	52	451	0.518	0.472
	Yes	132	21	153		
Locations of lymphadenovarix	No	147	18	165	2.422	0.490
	Upper neck	303	44	347		
	Lower neck	61	6	67		
	Superclavical	20	5	25		
Induction chemotherapeutic protocols	No	76	8	84	6.791	0.079
	Paclitaxel+platinum	395	49	444		
	Gemcitabine+platinum	10	3	13		
	Fluorouracil+platinum	50	13	63		
Retropharyngeal lymph node	No	114	14	128	0.202	0.653
	Yes	417	59	476		
Chemotherapeutic cycle	≤ 2 cycles	372	46	418	1.494	0.222
	≥ 3 cycles	159	27	186		
Extracapsular invasion of lymph node	No	208	26	234	0.342	0.559
	Yes	323	47	370		
Lost to follow-up	No	494	69	563	0.031	0.861
	Yes	37	4	41		
Death	Survival	401	24	425	55.959	<0.0001
	Died	130	49	179		
Metastasis	No	425	64	489	2.426	0.119
	Yes	106	9	115		

Table 2. Univariate Analysis on Influence of Each Factor on Recurrent Time

Influencing factors	1-year recurrent rate (%)	3-year recurrent rate (%)	5-year recurrent rate (%)	χ^2 value	P value
General	2.0	9.5	12.9	-	-
Gender					
Male	1.9	10.5	13.2	0.501	0.479
Female	2.2	6.1	12.0		
Clinical stages					
III	1.3	7.7	10.4	8.411	0.004
IV	3.5	13.1	18.3		
Radiotherapeutic techniques					
Routine radiotherapy	2.3	10.9	14.4	2.100	0.147
IMRT	1.5	6.6	10.2		
Extracapsular invasion of lymph node					
Yes	2.5	11.0	13.4	1.010	0.315
No	1.3	7.1	12.0		
Death					
Survival	0.0	2.1	5.1	129.815	<0.001
Died	7.0	33.0	40.4		

Table 3. Relevance between Metastasis and Each Factor

Influencing factors		Without metastasis (%)	With metastasis (%)	N	χ^2 value	P value
Gender	Males	369	97	466	4.172	0.041
	Females	120	18	138		
Ages	≤50	326	69	395	1.829	0.176
	>50	163	46	209		
Clinical patterns	Squamous carcinoma	468	107	575	1.444	0.230
	Non-squamous carcinoma	21	8	29		
T stages	1	38	10	48	7.7481	0.052
	2	53	8	61		
	3	285	57	342		
	4	113	40	153		
N stages	0	47	2	49	11.758	0.008
	1	206	42	248		
	2	192	55	247		
	3	44	16	60		
Clinical stages	III	339	62	401	9.911	0.002
	IV	150	53	203		
Raditherapeutic techniques	Routine radiotherapy	324	75	399	0.045	0.832
	IMRT	165	40	205		
Concurrent chemotherapy	No	368	83	451	0.468	0.494
	Yes	121	32	153		
Locations of lymphadenovarix	No	148	17	165	12.392	0.006
	Upper neck	273	74	347		
	Lower neck	50	17	67		
	Superclavical	18	7	25		
Induction chemotherapeutic protocols	No	64	20	84	3.703	0.295
	Paclitaxel+platinum	365	79	444		
	Gemcitabine+platinum	12	1	13		
	Fluorouracil+platinum	48	15	63		
Retropharyngeal lymph node	No	115	13	128	8.315	0.004
	Yes	374	102	476		
Chemotherapeutic cycle	≤2 cycles	343	75	418	1.060	0.303
	≥3 cycles	146	40	186		
Extracapsular invasion of lymph node	No	208	26	234	15.578	<0.001
	Yes	281	89	370		
Lost to follow-up	No	451	112	563	3.921	0.048
	Yes	38	3	41		
Death	Survival	407	18	425	203.903	<0.001
	Died	82	97	179		
Metastasis	No	425	106	531	2.426	0.119
	Yes	64	9	73		

Table 4. Univariate Analysis of Each Factor on Metastatic Period

Influencing factors	1-year metastatic rate (%)	3-year metastatic rate (%)	5-year metastatic rate (%)	χ^2 value	P value
General	6.6	17.5	18.8	—	—
Gender					
Males	7.5	19.6	20.6	4.578	0.032
Females	3.6	10.4	12.8		
Ages					
≤50 years	5.3	15.9	16.7	2.878	0.090
>50 years	9.2	20.5	22.9		
Pathological patterns					
Squamous carcinoma	6.5	17.1	18.3	1.659	0.198
Non-squamous carcinoma	10.3	24.3	28.3		
N stages					
0	0.0	2.2	4.6	12.182	0.007
1	4.8	14.7	16.5		
2	6.5	20.5	21.8		
3	20.0	26.8	26.8		
Clinical stages					
III	4.5	14.2	15.6	11.972	<0.001
IV	10.9	24.0	25.1		
Locations of lymphadenovarix					
No	1.8	9.5	10.9	12.874	0.005
Upper neck	6.7	18.8	20.5		
Lower neck	12.0	26.0	26.0		
Superclavical	24.0	28.2	28.2		
Retropharyngeal lymph node					
Yes	8.2	19.7	21.1	7.680	0.006
No	0.8	9.1	10.1		
Extracapsular invasion of lymph node					
Yes	9.5	22.1	23.7	16.255	<0.001
No	2.1	10.1	11.1		
Death					
Survival	0.9	2.6	3.3	301.451	<0.001
Died	20.4	57.5	62.3		
Induction chemotherapy					
Yes	6.0	16.6	17.9	1.560	0.212
No	10.8	23.2	24.5		
Inductive protocols					
Paclitaxel+platinum	6.1	16.1	17.6	2.502	0.286
Gemcitabine+platinum	0.0	7.7	7.7		
Fluorouraci+platinum	6.3	21.7	21.7		

Table 5. COX Regression Analysis on Influence of Each Factor on Metastatic Period

Influencing factors	Regression coefficient	P value	RR	95%CI	
				Lower limit	Upper limit
T stages	0.423	0.002	1.526	1.162	2.006
Induction protocols		0.088			
Induction protocol 1	-0.577	0.038	0.561	0.326	0.968
Induction protocol 2	-1.667	0.109	0.189	0.025	1.452
Induction protocol 3	-0.161	0.658	0.851	0.417	1.737
Extracapsular invasion of lymph node	0.544	0.050	1.723	0.999	2.970

Relevance between metastasis and each factor

The metastatic rates of females, and of patients in phase IV and those with retropharyngeal lymph node and extracapsular invasion of lymph node were relevantly higher; the larger the T stages, the higher the metastatic rate; the metastatic rate was the highest in patients with superclavical lymphadenovarix, followed by those with lower-neck and upper-neck lymphadenovarix, and the rate of those without lymphadenovarix was the lowest; it was higher in patients without lost to follow-up than those

with; it was higher in patients died than those survival and lost to follow-up; and there were significant differences in above comparison (Table 3). However, the metastatic rates of the rest factors had no significant difference (Table 3).

Influence of each factor on metastatic period

The life table method was applied to analyze the follow-up data of all patients, and the results indicated that the 1-, 3- and 5-year metastatic rates of LANPC patients were 6.6%, 17.5% and 18.8% respectively, with

the average recurrent period being 73 months (95% confidence intervals: 70.87~75.21 months).

In order to observe the influence of each factor on the metastatic period, log-rank test was adopted, in which T stages, N stages, radiotherapeutic techniques, concurrent chemotherapy, chemotherapeutic cycles and recurrence were excluded from the analysis due to their values, while the rest factor analysis results were shown in Table 4, which demonstrated that genders, N stages, clinical patterns, locations of lymphadenovarix, retropharyngeal lymph node, extracapsular invasion of lymph node and death had significant impact on the metastatic period of LANPC patients: the metastatic rates of females, and of patients in phase IV and those with retropharyngeal lymph node and extracapsular invasion of lymph node were relevantly higher; the larger the T stages, the higher the metastatic rate; the metastatic rate was the highest in patients with superclavical lymphadenovarix, followed by those with lower-neck and upper-neck lymphadenovarix, and the rate of those without lymphadenovarix was the lowest; it was higher in patients without lost to follow up than those with; it was higher in patients died than those survival and lost to follow up; and there were significant differences in above comparison; but the rest factors had no connection with the metastatic period.

On the basis of univariate analysis, genders, ages, pathological patterns, T stags, N stags, radiotherapeutic techniques, concurrent chemotherapy, locations of lymphadenovarix, induction chemotherapeutic protocols, retropharyngeal lymph node, chemotherapeutic cycles, extracapsular invasion of lymph node and metastasis were analyzed by multivariate analysis with COX risk ratio regression models (clinical stages were excluded from the analysis due to the high association with TNM stages). According to the COX regression analysis results, T stages, induction protocols and extracapsular invasion of lymph node were the independent prognostic factors for the metastasis of LANPC, and the metastasis was positively associated with T stages and extracapsular invasion of lymph node, which meant that T stages and extracapsular invasion of lymph node were the pestilent factors while reduction protocols the protective factor, and that the application of reduction protocols could greatly reduce the metastatic rates of LANPC patients (Table 5).

Discussion

With the continuous promotion of imaging technical techniques, improvement of radiotherapeutic techniques and the combined administration of radio- and chemotherapies, the survival rates of LANPC patients have been greatly increased. However, because LANPC patients are easy to have recurrence and metastasis, so recurrence and metastasis are still the major factors contributing to the post-radiotherapy death of LANPC patients (Dizman et al., 2014). Therefore, how to further control the therapeutic failure is of great significance. In addition, analysis on the clinical characteristics and the independent prognostic factors influencing the recurrence or metastasis of LANPC patients can devote contributions to seeking for more effective therapeutic methods for the

decrease of recurrence or metastasis.

The post-therapeutic recurrence/metastasis involves multiple factors including biological characteristics, clinical stages and therapeutic protocols, etc. the present studies believed that the recurrence was closely correlated with clinical stages in LANPC patients, and the recurrent rate was higher in advanced LANPC patients after initial comprehensive treatment (Li et al., 2012). Wang et al analyzed the factors with potential influences on the post-radiochemotherapeutic local control rate (LCR) of LANPC patients, in which the univariate analysis results revealed that the skull base bone destruction, T stages and pathological patterns diagnosed with MRI had significant impact on the LCR, and further COX regression analysis indicated that skull base bone destruction and pathological patterns diagnosed with MRI were the independent prognostic factors of the post-radiochemotherapeutic LCR of LANPC patients (Wang et al., 2014). Additionally, another study pointed out that the cranial nerve involvement and tumor response were closely connected with the distant metastatic rate, while ages, cranial nerve involvement, T stages and tumor response were the prognostic factors impacting the DMFS and disease-free survival time of LANPC patients (Demirci et al., 2011).

This study analyzed the clinical data of 604 patients initially diagnosed as LANPC without distant metastasis, and the results found that recurrence was in correlation with clinical stages and T stages, and further analysis on the influence of each factor on the metastatic period suggested that the clinical stages had obvious impact on the metastatic period of LANPC. However, there was no significant difference in COX regression equation after analysis, demonstrating that the factors selected in this study were not the independent prognostic factors influencing the recurrence, which was predicated to be associated with the fact that the application of IMRT and the comprehensive chemotherapies might lead to discrepant LCR to LANPC patients. The relevance analysis between each factor and the metastasis of cancerous cells showed that ages, clinical stages, retropharyngeal lymph nodes, extracapsular invasion of lymph node, N stages and locations of lymphadenovarix were in relation with the metastasis of cancerous cells, and further univariate and multivariate analysis about the influence of each factor on the metastasis of LANPC prompted that T stages, induction protocols and extracapsular invasion of lymph node were the independent prognostic factors for the metastasis of LANPC, and the metastasis was positively associated with T stages and extracapsular invasion of lymph node and negatively connected with induction protocols, which meant that T stages and extracapsular invasion of lymph node were the pestilent factors while induction protocols the protective factor, and that the application of induction chemotherapy could greatly reduce the metastatic rates of LANPC patients. There was significant difference in the recurrent and metastatic periods between patients with and without lost to follow up, which was predicated to be associated with the loss of data in this study. Moreover, this study also illustrated that the survival patients were significantly lower in recurrent

rate than those died, and death had obvious influence on the recurrent and metastatic periods, indicating that recurrence and metastasis were the major factors for the post-therapeutic death of LANPC patients.

To sum up, post-therapeutic metastasis were closely associated with T stages and extracapsular invasion of lymph node and the application of induction chemotherapy could greatly reduce the metastatic rates and then provide great benefits to LANPC patients.

Acknowledgements

This study was supported by Key Clinical Specialty Discipline Construction Program of Fujian, P.R.C. We wish to thank all members and patients involved to make this work successful. This study was supported by the National Clinical Key Specialty Construction Program, P.R.C, and Key Clinical Specialty Discipline Construction Program of Fujian, P.R.C.

References

- Chen JL, Huang YS, Kuo SH, et al (2013). Intensity-modulated radiation therapy for T4 nasopharyngeal carcinoma. *Strahlenther Onkol*, **189**, 1001-8.
- Demirci S, Kamer S, Kara G, et al (2011). Does the prognosis of nasopharyngeal cancer differ among endemic and non-endemic regions? *Acta Otolaryngol*, **131**, 852-60.
- Dizman A, Coskun-Breuneval M, Altinisik-Inan G, et al (2014). Reirradiation with robotic stereotactic body radiotherapy for recurrent nasopharyngeal carcinoma. *Asian Pac J Cancer Prev*, **15**, 3561-6.
- Hu S, Du J, Li D, et al (2014). Mitochondrial DNA haplogroup confers genetic susceptibility to nasopharyngeal carcinoma in chaoshanese from guangdong, china. *PLOS ONE*, **9**, 87795.
- Lee AW, Ng WT, Chan LLK, et al (2014). Evolution of treatment for nasopharyngeal cancer- Success and setback in the intensity-modulated radiotherapy era. *Radiother Oncol*, **110**, 377-84.
- Li JX, Lu TX, Huang Y, et al (2012). Clinical characteristics of recurrent nasopharyngeal carcinoma in high-incidence area. *Scientific World J*, **2012**, 719754.
- Li K, Lin GZ, Shen JC, et al (2014). Time trends of nasopharyngeal carcinoma in urban Guangzhou over a 12-year period (2000-2011): declines in both incidence and mortality. *Asian Pac J Cancer Prev*, **15**, 9899-903.
- Lin S, Pan J, Han L, Zhang X, et al (2009). Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. *Int J Radiat Oncol Biol Phys*, **75**, 1071-8.
- Lin SJ, Pan JJ, Han L, et al (2014). Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. *Radiother Oncol*, **110**, 385-9.
- Qu S, Liang ZG, Zhu XD (2015). Advances and challenges in intensity-modulated radiotherapy for nasopharyngeal carcinoma. *Asian Pac J Cancer Prev*, **16**, 1687-92.
- Wang Y, Zhao H, Zhang ZQ, et al (2014). MR imaging prediction of local control of nasopharyngeal carcinoma treated with radiation therapy and chemotherapy. *Br J Radiol*, **87**, 20130657.
- Wu F, Wang RS, Lu HM, et al (2014). Concurrent chemoradiotherapy in the locoregionally advanced nasopharyngeal carcinoma: Treatment outcomes of a

prospective, multicentric clinical study. *Radiother Oncol*, **112**, 106-11.

Wu SY, Wu YH, Yang MW, et al (2014). Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up. *Plos One*, **14**, 787.

Xu L, Pan J, Wu J, et al (2010). Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break. *Radiother Oncol*, **96**, 94-9.

Zeng L, Tian YM, Sun XM, et al (2014). Intensity-modulated radiotherapy for stage IVA/IVB nasopharyngeal carcinoma. *Strahlenther Onkol*, **190**, 993-1000.